美国的疫苗市场:各技术，各给药途径，各适应症，各年龄层，各流通管道，各地区，机会，预测，2018年～2032年

美国疫苗市场规模预计将从 2024 年的 222.3 亿美元增长到 2032 年的 346.4 亿美元，预测期内（2025-2032 年）的复合年增长率为 5.70%。

美国凭藉其强大的医疗保健体系、高疫苗接种率和大量的研发投入，引领全球疫苗市场。辉瑞、Moderna 和默克等顶级疫苗製造商的存在也支持了该地区的领导地位。这些公司在疫苗开发方面处于领先地位，特别是在mRNA技术领域。加拿大免疫计划和美国儿童疫苗（VFC）计划等政府计划确保了广泛的疫苗接种。

优惠的报销规定和高额的医疗支出进一步支撑了市场。该地区还受益于强有力的监管框架，FDA 和加拿大卫生部确保了疫苗的安全性和有效性。美国和加拿大在疫苗生产、製造和分发方面处于领先地位，进一步提升了美国在新冠疫情期间的市场主导地位。例如，B肝基金会大力支持美国疾病管制与预防中心（CDC）更新的成人B型肝炎疫苗指南。为了提高数百万美国成年人预防有害病毒的疫苗接种覆盖率，基金会正在积极与专家小组合作，支持成功实施这项建议。美国约有240万人患有慢性B型肝炎，每年夺走数千人的生命。

本报告提供美国的疫苗市场相关调查，提供市场概要，以及各技术，各给药途径，各适应症，各年龄层，各流通管道，各地区趋势，及加入此市场的主要企业简介等资讯。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 摘要整理

第4章 美国的疫苗市场预测，2018年～2032年

• 市场规模的分析与预测
• 市场占有率分析与预测
• 市场地图分析，2024年
  • 各技术
  • 各给药途径
  • 各适应症
  • 各年龄层
  • 各流通管道
  • 各地区

第5章 需求供给分析

第6章 价值链分析

第7章 波特的五力分析

第8章 大环境分析

第9章 价格分析

第10章 市场动态

第11章 市场趋势与发展

第12章 法规结构和革新

第13章 案例研究

第14章 竞争情形

• 前几名市场领导的竞争矩阵
• 前五名参与企业的SWOT分析
• 前10名市场主要企业的形势
  • Pfizer Inc.
  • Merck & Co., Inc.
  • GlaxoSmithKline plc
  • Moderna, Inc.
  • Sanofi S.A.
  • Novo Nordisk A/S
  • Serum Institute of India Pvt. Ltd.
  • China National Pharmaceutical Group Corporation (SINOPHARM)
  • Johnson & Johnson Services, Inc.
  • Sarepta Therapeutics, Inc.

第15章 策略性建议

第16章 关于调查公司·免责声明

United States vaccines market is projected to witness a CAGR of 5.70% during the forecast period 2025-2032, growing from USD 22.23 billion in 2024 to USD 34.64 billion in 2032.

The United States leads the world market for vaccines because of a robust healthcare system, high immunization rates, and substantial R&D expenditures. The presence of top vaccine producers like Pfizer, Moderna, and Merck aids the region's leadership. These businesses are leading the way in vaccine development, especially in the field of mRNA technology. Widespread vaccination distribution is guaranteed by government programs like Canada's immunization programs and the United States' Vaccines for Children (VFC) program. Advantageous reimbursement regulations and high healthcare spending further support the market. The FDA and Health Canada guarantee the safety and effectiveness of vaccines, and the region also benefits from robust regulatory frameworks. United States's dominant position in the market further improved during the COVID-19 epidemic, as the United States and Canada spearheaded the creation, manufacturing, and distribution of vaccines. With continuous advancements in vaccine technology and rising investments in immunization programs, the market will grow in the United States The Hepatitis B Foundation, for example, is a strong supporter of the United States Centers for Disease Control and Prevention's (CDC) updated guidelines for adult hepatitis B vaccine. To increase vaccine coverage against this harmful virus among millions of American adults, the Foundation is actively working with a panel of experts to support the successful implementation of these recommendations. About 2.4 million people in the United States have chronic hepatitis B, and the illness claims thousands of lives each year.

Technological Advancements Boosting Market Growth

The expansion of the vaccine market in the United States is boosting by transforming the processes of research, development, and production. Pfizer, Inc., BioNTech SE, and Moderna, Inc. were the first to create mRNA technology, which has raised the bar for quick vaccine production and allowed quicker reactions to new illnesses. By predicting virus alterations, optimizing clinical trials, and speeding up drug discovery, artificial intelligence (AI) and machine learning are simplifying vaccination research. Innovations in automation and bioprocessing, like cell-based manufacturing and single-use bioreactors, are increasing the scalability and efficiency of vaccine production. Through increased stability and immune response activation, nanotechnology is increasing vaccine delivery. Improved vaccine distribution and storage are made possible by sophisticated cold chain logistics, such as intelligent temperature monitoring and freeze-drying methods. Furthermore, the creation of next-generation vaccines is being aided by synthetic biology and CRISPR gene-editing technology. For instance, Emergent BioSolutions Inc. announced in July 2023, that the United States Food and Drug Administration (FDA) had approved CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis in persons 18 through 65 years of age when administered in conjunction with recommended antibacterial drugs. With ongoing innovation in biotechnology and digital healthcare, the United States vaccine market is poised for sustained growth and rapid advancements in immunization strategies. For instance, in February 2024, researchers from the University at Buffalo in the United States developed a promising recombinant flu vaccine using Nano-liposome technology.

Rising Numbers of Chronic Diseases Fueling Market Growth

Since people with diabetes, cancer, cardiovascular disease, and chronic respiratory illnesses are more likely to get infections, the growing frequency of chronic diseases is a significant factor driving the United States vaccination industry. These individuals are particularly vulnerable to vaccine-preventable illnesses like hepatitis, pneumonia, and influenza because they frequently have compromised immune systems. Because of this, medical professionals promote vaccination as a preventative strategy to lower hospitalizations and further possible problems. Pharmaceutical firms are spending money on customized vaccinations for people with weakened immune systems, such as enhanced influenza and pneumococcal vaccines. Furthermore, the growing prevalence of chronic diseases has sped up the creation of therapeutic vaccines, such those for cancer, which aim to boost the immune system's ability to combat malignancies. Government initiatives and insurance coverage for adult vaccinations further support market growth. With chronic disease cases rising due to aging populations and lifestyle factors, the demand for vaccines in the United States is expected to continue growing. For instance, in 2023, the United States reported 9,633 cases of TB disease. This represents an increase in case count of 15.6% compared with 2022.

Investments and Fundings Fueling Market Growth

Large investments made by the United States government and pharmaceutical companies are propelling the expansion of the United States vaccines market by speeding up research, development, and production. Rapid vaccine invention, especially in mRNA technology, has been made possible by government programs like Operation Warp Speed and continuous financing from organizations like the National Institutes of Health (NIH) and Biomedical Advanced Research and Development Authority (BARDA). These expenditures fund extensive immunization efforts and aid the fight against newly emerging infectious diseases. Additionally, pharmaceutical firms such as Pfizer Inc., Moderna Inc., and Merck Co. are making significant investments in next-generation vaccines to prevent respiratory infections, cancer, and other illnesses. Partnerships between the public and private sectors improve vaccine distribution and accessibility even more. For instance, CSL Limited established a new state-of-the-art vaccine R&D centre in Massachusetts. The R&D facility is equipped with 54,000 square feet of lab space, comprising Biosafety Level 3. The United States vaccines market is growing due to consistent funding support and strategic partnerships, which guarantees quicker reactions to health risks and better vaccination accessibility for a range of demographics.

Future Market Scenario (2025-2032F)

One of the main factors contributing to the anticipated growth of the vaccines market is the increasing demand for treatment options to ensure patient safety by delivering the right quality of drug or any other such chemical product. Not only that but the rising population and cases of chronic diseases such as cancer, is also a factor that will always propel market growth in future. Given that technology is advancing, we can expect cutting-edge technology in the area also. Players in this market are expanding at an un-paralleled rate, introducing cost-effective and efficient technologies. For instance, in August 2023, Pfizer, Inc., received the United States FDA approval for ABRYSVO, used for the prevention of lower respiratory tract disease (LRTD) and severe LRTD cause in infants from birth upto six months of age.

Key Players Landscape and Outlook

Key players in the vaccines industry utilize strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing big-cap industry players to increase their presence and, therefore, find new opportunities in this market.

For example, accessibility for people ages 2 to 49 was improved in September 2024 when the Food and Drug Administration (FDA) authorized the FluMist for self- or caregiver-administration. This permission made immunizations more convenient because they can now be given at home following a screening procedure. FluMist is authorized to protect people aged 2 to 49 from influenza illness brought on by influenza virus subtypes A and B.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. United States Vaccines Market Outlook, 2018-2032F

• 4.1. Market Size Analysis & Forecast
  • 4.1.1. By Value
  • 4.1.2. By Volume
• 4.2. Market Share Analysis & Forecast
  • 4.2.1. By Technology
    • 4.2.1.1. Live-attenuated Vaccines
    • 4.2.1.2. Inactivated Vaccines
    • 4.2.1.3. Subunit Vaccines
    • 4.2.1.4. mRNA Vaccines
    • 4.2.1.5. Viral Vector Vaccines
  • 4.2.2. By Route of Administration
    • 4.2.2.1. Parenteral
    • 4.2.2.2. Oral
    • 4.2.2.3. Others
  • 4.2.3. By Indication
    • 4.2.3.1. Viral Diseases
      • 4.2.3.1.1. Hepatitis
      • 4.2.3.1.2. Influenza
      • 4.2.3.1.3. Human papillomavirus (HPV)
      • 4.2.3.1.4. Measles, Mumps, and Rubella (MMR)
      • 4.2.3.1.5. Rotavirus
      • 4.2.3.1.6. Herpes Zoster
      • 4.2.3.1.7. Covid-19
      • 4.2.3.1.8. Others
    • 4.2.3.2. Bacterial Vaccines
      • 4.2.3.2.1. Meningococcal Diseases
      • 4.2.3.2.2. Pneumococcal diseases
      • 4.2.3.2.3. Diphtheria-Tetanus-Pertussis (DPT)
      • 4.2.3.2.4. Others
    • 4.2.3.3. Cancer Vaccines
    • 4.2.3.4. Allergy Vaccines
  • 4.2.4. By Age Group
    • 4.2.4.1. Adult
    • 4.2.4.2. Pediatric
  • 4.2.5. By Distribution Channel
    • 4.2.5.1. Hospital and Retail Pharmacies
    • 4.2.5.2. Government Suppliers and Authorities
    • 4.2.5.3. Others
  • 4.2.6. By Region
    • 4.2.6.1. Northeast
    • 4.2.6.2. Midwest
    • 4.2.6.3. West
    • 4.2.6.4. South
  • 4.2.7. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
• 4.3. Market Map Analysis, 2024
  • 4.3.1. By Technology
  • 4.3.2. By Route of Administration
  • 4.3.3. By Indication
  • 4.3.4. By Age Group
  • 4.3.5. By Distribution Channel
  • 4.3.6. By Region

5. Demand Supply Analysis

6. Value Chain Analysis

7. Porter's Five Forces Analysis

8. PESTLE Analysis

9. Pricing Analysis

10. Market Dynamics

• 10.1. Market Drivers
• 10.2. Market Challenges

11. Market Trends and Developments

12. Regulatory Framework and Innovation

• 12.1. Patent Landscape
• 12.2. Regulatory Approvals
• 12.3. Innovations/Emerging Technologies

13. Case Studies

14. Competitive Landscape

• 14.1. Competition Matrix of Top 5 Market Leaders
• 14.2. SWOT Analysis for Top 5 Players
• 14.3. Key Players Landscape for Top 10 Market Players
  • 14.3.1. Pfizer Inc.
    • 14.3.1.1. Company Details
    • 14.3.1.2. Key Management Personnel
    • 14.3.1.3. Products and Services
    • 14.3.1.4. Financials (As Reported)
    • 14.3.1.5. Key Market Focus and Geographical Presence
    • 14.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
  • 14.3.2. Merck & Co., Inc.
  • 14.3.3. GlaxoSmithKline plc
  • 14.3.4. Moderna, Inc.
  • 14.3.5. Sanofi S.A.
  • 14.3.6. Novo Nordisk A/S
  • 14.3.7. Serum Institute of India Pvt. Ltd.
  • 14.3.8. China National Pharmaceutical Group Corporation (SINOPHARM)
  • 14.3.9. Johnson & Johnson Services, Inc.
  • 14.3.10. Sarepta Therapeutics, Inc.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us and Disclaimer

List of Tables

• Table 1. Competition Matrix of Top 5 Market Leaders
• Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
• Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

• Figure 1. United States Vaccines Vehicle Market, By Value, In USD Billion, 2018-2032F
• Figure 2. United States Vaccines Vehicle Market, By Volume, In Units, 2018-2032F
• Figure 3. United States Vaccines Vehicle Market Share (%), By Technology, 2018-2032F
• Figure 4. United States Vaccines Vehicle Market Share (%), By Route of Administration, 2018-2032F
• Figure 5. United States Vaccines Vehicle Market Share (%), By Indication, 2018-2032F
• Figure 6. United States Vaccines Vehicle Market Share (%), By Age Group, 2018-2032F
• Figure 7. United States Vaccines Vehicle Market Share (%), By Distribution Channel, 2018-2032F
• Figure 8. United States Vaccines Vehicle Market Share (%), By Region, 2018-2032F
• Figure 9. By Technology Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 10. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 11. By Indication Size Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 12. By Age Group Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 13. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
• Figure 14. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024